Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …

Introduction: Leishmaniasis is a vector-borne neglected tropical disease which manifests as
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous …

Leishmaniasis is endemic in 88 countries on five continents. There are 1–1.5 million cases
of cutaneous leishmaniasis reported yearly worldwide. There has been a sharp increase in …

Cutaneous Leishmaniasis: Recognition and Treatment | AAFP Advertisement search close
brand logo WILLIAM H. MARKLE, MD, AND KHALDOUN MAKHOUL, MD Am Fam Physician …

Liposomal amphotericin B, which is injected infrequently and is easily tolerated, is virtually
100% effective for Indian visceral disease at a total dose of 15 mg/kg and is 90% effective at …

Estimated worldwide incidence of tegumentary leishmaniasis (cutaneous leishmaniasis [CL]
and mucocutaneous leishmaniasis [MCL]) is over 1.5 million cases per year in 82 countries …

Cutaneous leishmaniasis is one of the most common tropical dermatoses worldwide and is
of major public health importance. It is caused by numerous Leishmania protozoa species …

Background Sanliurfa is located in south‐east Anatolia, the region with the largest focus of
anthroponotic cutaneous leishmaniasis (CL) in Turkey. The present study was designed to …

Background Cutaneous leishmaniasis (CL) is a parasitic disease caused by Leishmania
species. There is a need for more effective and less time‐consuming therapeutic methods …

Background Cutaneous leishmaniasis (CL) is a vector‐born parasitic disease characterized
by various skin lesions that cause disfiguration if healed spontaneously. Although CL has …